In 2023, Oscar Health (NYSE: OSCR) reported a 47% increase in revenue to US$5.86b compared to the previous year. The company’s net loss decreased by 55% to US$270.7m, resulting in a loss of US$1.22 per share, an improvement from the US$2.85 loss in 2022.
Oscar Health’s earnings per share (EPS) beat analyst expectations by 5.8%, while revenue met estimates. Looking ahead, the company is forecasted to experience an average annual revenue growth of 27% over the next two years, significantly outperforming the expected 5.8% growth for the Insurance industry in the US.
The American Insurance industry has been performing well, with Oscar Health’s shares up by 26% from a week ago. However, there are two warning signs in the company’s investment analysis that investors should be aware of.
Investors can provide feedback on this article or express concerns about its content by contacting Simply Wall St’s editorial team. This article aims to provide general commentary based on historical data and analyst forecasts using an unbiased methodology and does not offer financial advice or take into account individual objectives or financial situations. Simply Wall St provides long-term focused analysis driven by fundamental data and may not factor in recent price-sensitive company announcements or qualitative information.
Simply Wall St does not hold positions in any mentioned stocks.